Identification
NameInfliximab
Accession NumberDB00065  (BTD00004, BIOD00004)
TypeBiotech
GroupsApproved
Description

Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion.

Protein structureDb00065
Related Articles
Protein chemical formulaC6428H9912N1694O1987S46
Protein average weight144190.3 Da
SequencesNot Available
Synonyms
Ig gamma-1 chain C region
External IDs ABP 710 / BOW015 / CT-P-13 / CT-P13 / TA-650
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
FlixabiInjection, powder, for solution100 mgIntravenousSamsung Bioepis Uk Limited (Sbuk)2016-05-26Not applicableEu
InflectraPowder, for solution100 mgIntravenousCelltrion2014-09-04Not applicableCanada
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraInjection, powder, lyophilized, for solution100 mg/10mLIntravenousPfizer Laboratories Div Pfizer Inc.2016-11-21Not applicableUs
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
InflectraInjection, powder, for solution100 mgIntravenousHospira, Inc.2013-09-10Not applicableEu
RemicadePowder, for solution100 mgIntravenousJanssen Pharmaceuticals2001-06-14Not applicableCanada
RemicadeInjection, powder, for solution100 mgIntravenousJanssen Biologics B.V.  1999-08-13Not applicableEu
RemicadeInjection, powder, for solution100 mgIntravenousJanssen Biologics B.V.  1999-08-13Not applicableEu
RemicadeInjection, powder, for solution100 mgIntravenousJanssen Biologics B.V.  1999-08-13Not applicableEu
RemicadeInjection, powder, for solution100 mgIntravenousJanssen Biologics B.V.  1999-08-13Not applicableEu
RemicadeInjection, powder, for solution100 mgIntravenousJanssen Biologics B.V.  1999-08-13Not applicableEu
RemsimaPowder, for solution100 mgIntravenousCelltrion2014-09-18Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIB72HH48FLU
CAS number170277-31-3
Pharmacology
Indication

To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.

Structured Indications
Pharmacodynamics

Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.

Mechanism of action

Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. TNFa activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation.

TargetKindPharmacological actionActionsOrganismUniProt ID
Tumor necrosis factorProteinyes
inhibitor
HumanP01375 details
Related Articles
Absorption

Onset of action occurs in about 2 weeks in Crohn's disease.

Volume of distribution

3-6 L

Protein bindingNot Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. Not metabolized by the CYP enzymes.

Route of eliminationNot Available
Half life

9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis

ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Low affinity immunoglobulin gamma Fc region receptor III-A---(C;C)CC Allele (homozygous) Effect Directly StudiedBetter ACR20 response Details
Interactions
Drug Interactions
DrugInteractionDrug group
AbataceptThe risk or severity of adverse effects can be increased when Infliximab is combined with Abatacept.Approved
AdalimumabAdalimumab may increase the immunosuppressive activities of Infliximab.Approved
AnakinraThe risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.Approved
BelimumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Canakinumab.Approved, Investigational
Certolizumab pegolInfliximab may increase the immunosuppressive activities of Certolizumab pegol.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.Approved
EtanerceptEtanercept may increase the immunosuppressive activities of Infliximab.Approved, Investigational
FingolimodInfliximab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Infliximab is combined with G17DT.Investigational
GolimumabGolimumab may increase the immunosuppressive activities of Infliximab.Approved
INGN 201The risk or severity of adverse effects can be increased when Infliximab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Infliximab is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Infliximab is combined with CDX-110.Investigational
RituximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Infliximab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.Approved
SRP 299The risk or severity of adverse effects can be increased when Infliximab is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab.Approved, Investigational
TocilizumabTocilizumab may increase the immunosuppressive activities of Infliximab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Infliximab.Approved, Investigational
UstekinumabUstekinumab may increase the immunosuppressive activities of Infliximab.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Infliximab is combined with Vedolizumab.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443-53. [PubMed:8232330 ]
  2. Dubinsky MC, Fleshner PP: Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. Curr Treat Options Gastroenterol. 2003 Jun;6(3):183-200. [PubMed:12744819 ]
  3. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405. [PubMed:10228190 ]
  4. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85. [PubMed:14985485 ]
  5. Hanauer SB: Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):131-7. [PubMed:12617888 ]
  6. Link [Link]
  7. Link [Link]
External Links
ATC CodesL04AB02
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (1.21 MB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
1CompletedPreventionReperfusion Injury1
1CompletedTreatmentAnkylosing Spondylitis (AS)3
1CompletedTreatmentGraft Versus Host Disease (GVHD)1
1CompletedTreatmentMucocutaneous Lymph Node Syndrome1
1CompletedTreatmentRheumatoid Arthritis1
1CompletedTreatmentScleritis1
1Not Yet RecruitingTreatmentSterile Corneal Melt1
1RecruitingTreatmentDepression1
1, 2Not Yet RecruitingTreatmentAneurysms / Stroke / Tumor Necrosis Factor-alpha / Vasculitis1
1, 2TerminatedTreatmentBerylliosis / Beryllium Disease1
1, 2TerminatedTreatmentChronic Granulomatous Disease (CGD) / Crohn'S-like IBD / Inflammatory Bowel Diseases (IBD)1
1, 2Unknown StatusTreatmentDiabetic Macular Edema (DME)1
1, 2WithdrawnPreventionMucous Membrane Pemphigoid / Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (Lyell) Syndrome1
1, 2WithdrawnTreatmentCorneal Blindness / Stevens-Johnson Syndrome1
1, 2WithdrawnTreatmentIntraocular Inflammation / Uveitic Macular Edema1
2Active Not RecruitingTreatmentAcute GVH Disease / Graft Versus Host Disease (GVHD) / Steroid Refractory GVHD1
2Active Not RecruitingTreatmentLung Cancers / Melanoma / Renal Cell Carcinoma (RCC)1
2CompletedPreventionGraft Versus Host Disease (GVHD)1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentCachexia / Chronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentCachexia / Neoplasms, Pancreatic1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentDermatomyositis / Polymyositis1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentEsophagitis1
2CompletedTreatmentHepatitis C1
2CompletedTreatmentHidradenitis Suppurativa (HS)1
2CompletedTreatmentMicroscopic Polyangiitis / Renal Limited Vasculitis / Wegener Granulomatosis (WG)1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentPemphigus1
2CompletedTreatmentPsoriasis2
2CompletedTreatmentRheumatoid Arthritis3
2Not Yet RecruitingTreatmentIdiopathic Refractory Scleritis1
2RecruitingTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2RecruitingTreatmentDepression, Bipolar1
2RecruitingTreatmentReperfusion Injury1
2RecruitingTreatmentTakayasu's Arteritis1
2RecruitingTreatmentTransplant, Kidney1
2TerminatedSupportive CareCancer, Breast / Lethargy1
2TerminatedTreatmentArthritis, Juvenile Rheumatoid1
2TerminatedTreatmentGiant Cell Arteritis1
2TerminatedTreatmentHTLV-I-Associated Myelopathy1
2TerminatedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentSpondylarthropathy1
2Unknown StatusEducational/Counseling/TrainingReactive Arthritis1
2WithdrawnTreatmentColitis / Cytokines / Drug Evaluation / Hermanski-Pudlak Syndrome / Lymphocytes1
2WithdrawnTreatmentToxic Epidermal Necrolysis1
2, 3CompletedNot AvailableAnkylosing Spondylitis (AS)1
2, 3CompletedTreatmentCrohn's Disease (CD)1
2, 3CompletedTreatmentRefractory Myositis1
2, 3CompletedTreatmentSpondylarthropathy1
2, 3RecruitingTreatmentCrohn's Disease (CD)1
2, 3TerminatedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1
2, 3Unknown StatusTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
2, 3WithdrawnTreatmentArthritis1
3Active Not RecruitingTreatmentAnkylosing Spondylitis (AS)1
3Active Not RecruitingTreatmentRheumatoid Arthritis2
3CompletedBasic ScienceCrohn's Disease (CD)1
3CompletedSupportive CareAnorexia / Cachexia / Lethargy / Lung Cancers1
3CompletedTreatmentAnkylosing Spondylitis (AS)3
3CompletedTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
3CompletedTreatmentBehcet's Disease / Behcet's Syndrome / Neuro-Behcet's Disease1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentCrohn's Disease (CD)7
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3CompletedTreatmentKawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin1
3CompletedTreatmentMucocutaneous Lymph Node Syndrome2
3CompletedTreatmentPalmoplantar Psoriasis1
3CompletedTreatmentParapsoriasis / Psoriasis1
3CompletedTreatmentPediatric Crohn's Disease1
3CompletedTreatmentPediatric Ulcerative Colitis1
3CompletedTreatmentPlaque Psoriasis / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular Psoriasis (Excluding a Localized)1
3CompletedTreatmentPsoriasis7
3CompletedTreatmentPsoriatic Arthritis2
3CompletedTreatmentRheumatoid Arthritis12
3CompletedTreatmentRheumatoid Arthritis, Juvenile1
3CompletedTreatmentSarcoidosis1
3CompletedTreatmentUlcerative Colitis (UC)4
3Not Yet RecruitingTreatmentGraft Versus Host Disease (GVHD)1
3Not Yet RecruitingTreatmentRheumatoid Arthritis1
3RecruitingPreventionCrohn's Disease (CD)1
3RecruitingTreatmentBehcet's Disease1
3RecruitingTreatmentMucocutaneous Lymph Node Syndrome1
3RecruitingTreatmentRheumatoid Arthritis3
3RecruitingTreatmentUlcerative Colitis (UC)1
3TerminatedPreventionCrohn's Disease (CD)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentDiabetic Macular Edema (DME) / Retinopathy, Diabetic / Visual Acuity1
3TerminatedTreatmentPsoriasis2
3TerminatedTreatmentRheumatoid Arthritis1
3TerminatedTreatmentUlcerative Colitis (UC)2
3Unknown StatusTreatmentCrohn's Disease (CD)1
3Unknown StatusTreatmentPolymyalgia Rheumatica1
4Active Not RecruitingTreatmentCrohn's Disease (CD) / Psoriasis Chronic / Psoriatic Arthritis / Rheumatoid Arthritis / Spondyloarthritis / Ulcerative Colitis (UC)1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4CompletedNot AvailableAnkylosing Spondylitis (AS) / Crohn's Disease (CD)1
4CompletedNot AvailableAnkylosing Spondylitis (AS) / Psoriasis / Psoriatic Arthritis / Rheumatoid Arthritis1
4CompletedNot AvailableCrohn's Disease (CD) / Psoriasis / Rheumatoid Arthritis1
4CompletedNot AvailableRheumatoid Arthritis1
4CompletedNot AvailableUlcerative Colitis (UC)2
4CompletedDiagnosticAnkylosing Spondylitis (AS)1
4CompletedPreventionCrohn's Disease (CD)1
4CompletedTreatmentAnkylosing Spondylitis (AS)4
4CompletedTreatmentAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Spondylarthropathy1
4CompletedTreatmentBMI >30 kg/m2 / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentChronic Uveitis1
4CompletedTreatmentCrohn's Disease (CD)2
4CompletedTreatmentCrohn's Disease (CD) / Psoriasis / Psoriatic Arthritis / Rheumatoid Arthritis1
4CompletedTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4CompletedTreatmentDepression1
4CompletedTreatmentGraft Versus Host Disease (GVHD)1
4CompletedTreatmentOsteoarthritis,Knee1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPsoriatic Arthritis1
4CompletedTreatmentRheumatoid Arthritis7
4CompletedTreatmentSpondylitis1
4CompletedTreatmentUlcerative Colitis (UC)1
4CompletedTreatmentUveitis1
4Enrolling by InvitationBasic ScienceRheumatoid Arthritis1
4Enrolling by InvitationTreatmentCrohn's Disease (CD)1
4Not Yet RecruitingTreatmentDepression1
4Not Yet RecruitingTreatmentRheumatoid Arthritis2
4Not Yet RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingBasic ScienceRheumatoid Arthritis1
4RecruitingTreatmentCrohn's Disease (CD)1
4RecruitingTreatmentHypertensive1
4RecruitingTreatmentInflammatory Bowel Diseases (IBD)1
4RecruitingTreatmentRheumatoid Arthritis4
4RecruitingTreatmentUlcerative Colitis (UC)2
4TerminatedDiagnostic(SpA) / Ankylosing Spondylitis (AS)1
4TerminatedTreatmentCrohn's Disease (CD)2
4Unknown StatusBasic ScienceAbsolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern / Psoriasis, Moderate to Severe1
4Unknown StatusScreeningAnkylosing Spondylitis (AS) / Rheumatoid Arthritis1
4Unknown StatusTreatmentAnkylosing Spondylitis (AS) / Hypertensive / Psoriatic Arthritis / Rheumatoid Arthritis1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentInfliximab / Rheumatoid Arthritis / Ultrasonography1
4Unknown StatusTreatmentRheumatoid Arthritis2
4WithdrawnTreatmentAnkylosing Spondylitis (AS)1
4WithdrawnTreatmentPediatric Crohn's Disease1
Not AvailableActive Not RecruitingNot AvailableCrohn's Disease (CD)1
Not AvailableActive Not RecruitingNot AvailablePsoriasis / Psoriatic Arthritis1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS)2
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS) / Crohn's Disease (CD) / Psoriasis / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableAtherosclerosis / Moderate, refractory Atopic dermatitis / Psoriasis1
Not AvailableCompletedNot AvailableCrohn's Disease (CD)5
Not AvailableCompletedNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD) / Psoriasis1
Not AvailableCompletedNot AvailablePsoriasis4
Not AvailableCompletedNot AvailablePsoriatic Arthritis1
Not AvailableCompletedNot AvailableRheumatoid Arthritis6
Not AvailableCompletedNot AvailableSpondyloarthritis / Ultrasonography1
Not AvailableCompletedNot AvailableUveitis1
Not AvailableCompletedBasic ScienceRheumatoid Arthritis1
Not AvailableCompletedScreeningTransplantation, Kidney1
Not AvailableCompletedTreatmentChurg-Strauss Syndrome (CSS) / Microscopic Polyangiitis / Wegener Granulomatosis (WG)1
Not AvailableCompletedTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Pyoderma Gangrenosum / Ulcerative Colitis (UC)1
Not AvailableCompletedTreatmentRheumatoid Arthritis1
Not AvailableCompletedTreatmentUndifferentiated Arthritis1
Not AvailableEnrolling by InvitationNot AvailableCrohn's Disease (CD)1
Not AvailableNot Yet RecruitingTreatmentPediatric Crohns Disease1
Not AvailableRecruitingNot AvailableAnkylosing Spondylitis (AS)1
Not AvailableRecruitingNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis2
Not AvailableRecruitingNot AvailableBowel Diseases, Inflammatory / Ulcerative Colitis (UC)1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / IBD1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)2
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
Not AvailableRecruitingNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableRecruitingNot AvailablePsoriasis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis3
Not AvailableRecruitingDiagnosticIBD1
Not AvailableTerminatedNot AvailableCrohn's Disease (CD)2
Not AvailableTerminatedNot AvailableMelanoma1
Not AvailableTerminatedTreatmentCrohn's Disease (CD)1
Not AvailableUnknown StatusNot AvailableCrohn's Disease (CD)1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusNot AvailableSerological C Reactive Protein or Erythrocyte Sedimentation Rate1
Not AvailableUnknown StatusTreatmentAnkylosing Spondylitis (AS)1
Not AvailableUnknown StatusTreatmentCrohn's Disease (CD)1
Not AvailableUnknown StatusTreatmentPsoriasis1
Not AvailableWithdrawnNot AvailableRheumatoid Arthritis1
Pharmacoeconomics
Manufacturers
  • J&J and Mitsubisi Tanabe
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous100 mg
Injection, powder, lyophilized, for solutionIntravenous100 mg/10mL
Powder, for solutionIntravenous100 mg
Prices
Unit descriptionCostUnit
Remicade 100 mg Solution Vial821.02USD vial
Remicade 100 mg vial789.44USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2106299 No2001-02-062012-03-18Canada
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
hydrophobicity-0.441Not Available
isoelectric point8.25Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Mimura T: [Selection of one of the TNF blockers; infliximab and etanercept]. Nihon Rinsho. 2007 Jul;65(7):1282-6. [PubMed:17642244 ]
  3. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51. [PubMed:16052578 ]
  4. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24. [PubMed:16456024 ]
  5. Magro F, Pereira P, Carneiro F, Veloso FT: Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005 Jan;11(1):88-90. [PubMed:15674127 ]
  6. Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M: Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62. [PubMed:16622728 ]
  7. Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27. [PubMed:12110154 ]
  8. Sapienza MS, Cohen S, Dimarino AJ: Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004 Sep;49(9):1454-7. [PubMed:15481318 ]
  9. Tobin AM, Kirby B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57. [PubMed:15691217 ]
  10. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8. [PubMed:15691299 ]
  11. Popa C, Netea MG, Barrera P, Radstake TR, van Riel PL, Kullberg BJ, Van der Meer JW: Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 2005 Apr 21;30(2):72-7. [PubMed:15804598 ]
Drug created on June 13, 2005 07:24 / Updated on April 27, 2017 13:58